Table of Contents
International Scholarly Research Notices
Volume 2014 (2014), Article ID 701493, 16 pages
http://dx.doi.org/10.1155/2014/701493
Review Article

Target Therapy in Hematological Malignances: New Monoclonal Antibodies

1Department of Hematooncology and Bone Marrow Transplantation, Medical University of Lublin, Staszica 11, 20-081 Lublin, Poland
2Students Scientific Association at the Department of Hematooncology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Poland

Received 10 April 2014; Revised 22 September 2014; Accepted 23 September 2014; Published 30 October 2014

Academic Editor: Paola Perego

Copyright © 2014 Monika Podhorecka et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Apart from radio- and chemotherapy, monoclonal antibodies (MoAbs) represent a new, more selective tool in the treatment of hematological malignancies. MoAbs bind with the specific antigens of the tumors. This interaction is a basis for targeted therapies which exhibit few side effects and significant antitumor activity. This review provides an overview of the functional characteristics of MoAbs, with some examples of their clinical application. The promising results in the treatment of hematological malignancies have led to the more frequent usage of MoAbs in the therapy. Development of MoAbs is a subject of extensive research. They are a promising method of cancer treatment in the future.